Qiagen further invests in cancer Dx portfolio with Ipsogen buy
This article was originally published in Clinica
Executive Summary
Qiagen is set to acquire Ipsogen, a French specialist in blood cancers diagnostics, in a deal worth $101m. The move, which follows a flurry of investments made by the Dutch firm over the last few months, underlines its strategy to build critical mass in the molecular diagnostics field.